This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Genentech, Inc., National Cancer Center, Ventana Medical Systems, Inc.. Active years: 2026.
Company Filing History:
1 out of 3,292 
1 out of 263 
1 out of 548 
Years Active: 2026
Title: Amy A Lo: Innovator in Cancer Biomarkers
Introduction
Amy A Lo is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of cancer research, particularly in the area of biomarkers. Her innovative work focuses on improving the predictability of responses to HER2-directed therapies in cancer treatment.
Latest Patents
Amy A Lo holds a patent titled "HER2 heterogeneity as a biomarker in cancer." This patent describes a method for predicting responsiveness to HER2-directed therapy by assessing HER2 heterogeneity in tumors. The method involves contacting a tumor sample with a biomarker-specific reagent that binds to HER2 protein, detecting HER2 protein in the sample, and evaluating HER2 gene amplification and RNA status. The scoring of HER2 protein, gene, and RNA allows for the prediction of tumor responsiveness to therapy based on varying scores.
Career Highlights
Throughout her career, Amy has worked with notable organizations such as Genentech, Inc. and the National Cancer Center. Her experience in these institutions has allowed her to develop and refine her innovative approaches to cancer treatment.
Collaborations
Amy has collaborated with esteemed colleagues, including Adrian E Murillo and Hiro Nitta. These partnerships have further enhanced her research and contributions to the field.
Conclusion
Amy A Lo is a trailblazer in cancer biomarker research, with her patent and collaborations paving the way for advancements in personalized cancer therapies. Her work continues to impact the medical community and improve patient outcomes.